Sinew Pharma Inc.
Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also… Read more
Sinew Pharma Inc. (6634) - Total Assets
Latest total assets as of June 2025: NT$1.18 Billion TWD
Based on the latest financial reports, Sinew Pharma Inc. (6634) holds total assets worth NT$1.18 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sinew Pharma Inc. - Total Assets Trend (2019–2024)
This chart illustrates how Sinew Pharma Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sinew Pharma Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Sinew Pharma Inc.'s total assets of NT$1.18 Billion consist of 96.3% current assets and 3.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 3.4% |
| Accounts Receivable | NT$2.42 Million | 0.2% |
| Inventory | NT$0.00 | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$22.27 Million | 1.8% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Sinew Pharma Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sinew Pharma Inc.'s current assets represent 96.3% of total assets in 2024, an increase from 72.7% in 2019.
- Cash Position: Cash and equivalents constituted 3.4% of total assets in 2024, down from 60.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 1.8% of total assets.
Sinew Pharma Inc. Competitors by Total Assets
Key competitors of Sinew Pharma Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Sinew Pharma Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Sinew Pharma Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Sinew Pharma Inc. is currently not profitable relative to its asset base.
Sinew Pharma Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 53.40 | 44.44 | 2.50 |
| Quick Ratio | 53.40 | 44.44 | 2.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.11 Billion | NT$ 1.21 Billion | NT$ 197.24 Million |
Sinew Pharma Inc. - Advanced Valuation Insights
This section examines the relationship between Sinew Pharma Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.10 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -10.1% |
| Total Assets | NT$1.23 Billion |
| Market Capitalization | $45.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sinew Pharma Inc.'s assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sinew Pharma Inc.'s assets decreased by 10.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sinew Pharma Inc. (2019–2024)
The table below shows the annual total assets of Sinew Pharma Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.23 Billion | -10.07% |
| 2023-12-31 | NT$1.36 Billion | -8.32% |
| 2022-12-31 | NT$1.49 Billion | -6.16% |
| 2021-12-31 | NT$1.58 Billion | +249.71% |
| 2020-12-31 | NT$453.16 Million | +7.70% |
| 2019-12-31 | NT$420.78 Million | -- |